文献速递乳房整形与再造

即刻两阶段假体乳房再造失败:放疗并非唯一原因

Immediate Two-Stage Prosthetic Breast Reconstruction Failure: Radiation Is Not the Only Culprit.
PubMed 文献 · Plast Reconstr Surg · 2018-01-01

该回顾性队列研究纳入1998至2010年间452例患者共562侧乳房,分析即刻两阶段假体乳房再造后假体丢失等并发症。结果显示化疗和放疗均为假体丢失的独立危险因素,化疗联合放疗风险最高,放疗在化疗基础上使假体丢失风险加倍,但在多学科协作下仍属可接受选择。

要点

  • 化疗和放疗是假体丢失的独立危险因素,发生率比分别为13.85和2.23。
  • 化疗联合放疗者假体丢失发生率比为4.791,风险进一步升高。
  • 放疗在化疗基础上使假体丢失风险加倍,但多学科协作下仍可接受。

核心结论

  • 术后放疗在辅助化疗基础上使假体丢失风险加倍,但在多学科协作下,即刻两阶段假体乳房再造后放疗是可接受的选择。

研究设计与样本

  • 回顾性队列研究,纳入1998年至2010年间452例接受即刻两阶段假体乳房再造的患者,共562侧乳房。

主要发现

  • 总体假体丢失率为2.7%,接受辅助化疗者为5.3%,接受化疗联合放疗者升至11.3%。
  • 化疗和放疗分别为假体或扩张器丢失的独立显著危险因素,发生率比分别为13.85(p=0.012)和2.23(p=0.027)。
  • 化疗联合放疗者的假体丢失亦显著,发生率比为4.791(p<0.001)。

临床怎么用

  • 作者认为这些发现有助于患者权衡治疗选择时更好地了解风险。
  • 作者认为术后放疗在辅助化疗基础上使假体丢失风险加倍,但在多学科协作下仍是即刻两阶段假体乳房再造后可接受的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immediate prosthetic breast reconstruction produces a satisfactory aesthetic result with high levels of patient satisfaction. However, with the broader indication for postmastectomy adjuvant radiation therapy, many patients are advised against immediate breast reconstruction because of concerns of implant loss and infection, particularly as most patients also require chemotherapy. This retrospective cohort study examines outcomes for patients who underwent immediate two-stage prosthetic breast reconstruction after mastectomy with or without adjuvant chemotherapy or radiotherapy. METHODS: Between 1998 and 2010, 452 patients undergoing immediate two-stage prosthetic breast reconstruction involving a total of 562 breasts were included in this study. Stage 1 was defined as insertion of the temporary expander, and stage 2 was defined as insertion of the final silicone implant. Postoperative adjuvant radiotherapy was recommended with a tissue expander in situ for 114 patients. Complications, including loss of prosthesis, seroma, and infection, were recorded and analyzed. Cosmetic result was assessed using a four-point scale. RESULTS: Postoperative prosthesis loss was 2.7 percent, 5.3 percent for patients undergoing adjuvant chemotherapy and increasing to 11.3 percent for patients receiving chemotherapy plus radiotherapy. Chemotherapy and radiotherapy independently were the main, statistically significant risk factors for expander or implant loss [incidence rate ratio, 13.85 (p = 0.012) and 2.23 (p = 0.027), respectively]. Prosthesis loss for patients undergoing combination chemotherapy plus radiotherapy was also significant [incidence rate ratio, 4.791 (p < 0.001)]. CONCLUSIONS: These findings serve to better inform patients on risk in weighing treatment options. Postmastectomy radiation therapy doubles the risk of prosthesis loss over and above adjuvant chemotherapy but is an acceptable option following immediate two-stage prosthetic breast reconstruction in a multidisciplinary setting. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Lam TC, Borotkanics R, Hsieh F, et al. Immediate Two-Stage Prosthetic Breast Reconstruction Failure: Radiation Is Not the Only Culprit. Plast Reconstr Surg. 2018. PMID: 29750759. doi:10.1097/PRS.0000000000004358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。